Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
16. November 2015 16:05 ET
|
Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...